The myogenic determination factors (MDFs) are transcriptional activators that target E boxes in many muscle-specific promoters, including those of the genes coding for the subunits of the acetylcholine receptor. It is not known, however, if in vivo a given E box in a transcriptionally active gene is occupied, either uniquely by one MDF or randomly by all MDFs. We have analyzed expression of MDF and acetylcholine receptor subunits in cultured mouse muscle cells and, using chromatin immunoprecipitation, have determined which individual MDFs reside at promoters of several receptor subunit genes. We find that before fusion, C2C12 cells express myf-5, MyoD, and myogenin, all of which take up residence at promoters of all subunits except ⑀. At this stage, herculin is present in limited amounts and is detected mainly at the ␥ and ␦ subunit genes. On myotube formation, herculin reaches high levels; concomitantly, the ⑀ subunit gene becomes a common MDF target and begins to be expressed. In general, any MDF protein that is expressed also is present on transcriptionally active receptor genes; transcriptional activity of target genes correlates with occupancy by MDF, in particular, herculin.
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The myogenic determination factors (MDFs) are transcriptional activators that target E boxes in many muscle-specific promoters, including those of the genes coding for the subunits of the acetylcholine receptor. It is not known, however, if in vivo a given E box in a transcriptionally active gene is occupied, either uniquely by one MDF or randomly by all MDFs. We have analyzed expression of MDF and acetylcholine receptor subunits in cultured mouse muscle cells and, using chromatin immunoprecipitation, have determined which individual MDFs reside at promoters of several receptor subunit genes. We find that before fusion, C2C12 cells express myf-5, MyoD, and myogenin, all of which take up residence at promoters of all subunits except ⑀. At this stage, herculin is present in limited amounts and is detected mainly at the ␥ and ␦ subunit genes. On myotube formation, herculin reaches high levels; concomitantly, the ⑀ subunit gene becomes a common MDF target and begins to be expressed. In general, any MDF protein that is expressed also is present on transcriptionally active receptor genes; transcriptional activity of target genes correlates with occupancy by MDF, in particular, herculin.
In skeletal muscle a family of transcription factors, the myogenic determination factors (MDFs) 1 MyoD, myogenin, myf-5, and MRF4, herculin, or myf-6, 2 recognize a 6-base pair element, the CANNTG motif or E box, to activate a large number of genes (1) . Although in vitro any one of these proteins, with the assistance of a member of the E protein family, binds to E box-containing promoters, it is not known in specific cases which one of these factors actually activates a given gene in vivo. Binding site selection experiments have not led to the identification of unique structural features, such as flanking regions or central base pairs, that are sufficiently distinctive for MyoD and myogenin to predict with confidence which one of these proteins will target an actual E box in a muscle gene promoter (2, 3) . This also holds for the MDF responsible for the expression of the genes coding for the acetylcholine receptor (AChR), a crucial component of the neuromuscular junction.
Several approaches are conceivable for elucidating specific MDF-E box interactions as they relate to the control of AChR expression. Electrophoretic mobility shift analysis reveals which factor or factor combination can recognize a given CANNTG element or whether a cellular extract contains E box binding activity. Using different DNA probes, such extracts can be shown to discriminate between E boxes. Thus, muscle nuclear extracts clearly discriminate between the two E boxes in the chick ␣ subunit enhancer (4) . A variant of mobility shift analysis is the "supershift" assay whereby factors present in nuclear extracts are identified through the effect of antibodies on protein-DNA complexes; this approach has been used to implicate the ETS protein GABP as the transcription factor that targets the N box, a motif mediating synapse-specific expression of the AChR ␦ and ⑀ subunits (5, 6) . The method presupposes that protein-DNA complexes, formed in the intact cell and dissociated subsequently during high-salt extraction of nuclear proteins, spontaneously and correctly reassemble in vitro. The validity of this assumption appears problematic in cases in which a cis element may be targeted by multiple factors that are expressed, and presumably active, in the cell or tissue under investigation.
It is also possible to test whether a given factor activates a specific cis element in a heterologous expression system. Numerous such studies have been conducted and, in general, have suggested that any of the four MDFs can drive any of the AChR promoters (7) (8) (9) (10) (11) (12) . Although transactivation results are difficult to interpret because the transgene is usually overexpressed, occasionally the relative efficacy of factors and therefore their likelihood to be active or inert in vivo can be assessed. For example, Dü rr et al. (13) found that myogenin and myf-5 are much more active at the rat ␥ promoter E boxes than MyoD and herculin; similarly, Berberich et al. (14) showed that the rat AChR ␤ subunit gene can be transactivated by myogenin as well as herculin and myf-5, whereas it responds much more weakly to MyoD.
One might try to elucidate the role of individual MDFs through spatiotemporal correlation of the expression of MDFs and the genes potentially dependent on them. In general, however, during skeletal muscle development, the expression of the four MDF genes does not often coincide with that of structural genes (15) . Changes in receptor expression can be induced in adult muscle by denervation and electromechanical stimulation. Thus motor nerve section is followed by enhanced expression of AChR subunits and up-regulation of MDF, especially of myogenin (16 -21) , which therefore is the transcription factor most likely to be involved in the activation of the genes encod-ing the ␥ isoform of the AChR. Direct evidence, however, is lacking.
Finally, one can attempt to specifically block expression of a suspected candidate protein. In particular, targeted gene disruption should shed light on the function of a specific factor. Experiments in which all four MDFs have been knocked out individually and in combination have led to the realization of considerable redundancy of function and an appreciation of the global role of individual myogenic determination factors but have not really brought us closer to an identification of specific target genes (see Ref. 22) . Antisense oligonucleotides could be used to show dependence on a specific MDF. Brunetti and Goldfine (23) blocked AChR expression in the BC3H1 tumor cell line using anti-myogenin oligonucleotides. Although remarkable, this finding is not specific enough. Any of several E boxes in any or all of the four subunit genes could be dependent on myogenin; in addition, because BC3H1 cells lack MyoD, the experiment leaves open the question of to what extent MyoD might be involved in AChR expression in normal muscle tissue. Finally, as in the other in vivo approaches mentioned, the experiments do not clarify whether a factor acts directly on the gene of interest or instead through the induction of an intermediary transcription factor.
This discouraging situation has changed recently with the introduction of the chromatin immunoprecipitation assay. We have used this technique to identify transcription factors targeting four AChR subunit genes in several mouse myogenic cell lines. We find that all MDFs that are expressed also participate in AChR gene transcription.
EXPERIMENTAL PROCEDURES
Reagents-Chemicals were from either Sigma or Fisher unless stated otherwise. Polyclonal antibodies to human MyoD, myogenin, myf-5, and myf-6, which cross-react with the homologous mouse proteins, and an anti-rabbit IgG-horseradish peroxidase conjugate were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Primers for the enhancers of different AChR subunit genes were designed to encompass E boxes for which involvement in subunit gene activity had previously been ascertained (sense and antisense, respectively): ␣ subunit, 5Ј-GA-CAAGCCTCTGACTCATGATCTATGT-3Ј and 5Ј-GCTGCCGGTCCTA-CTCCACCCTGGCT-3Ј; ␥ subunit, 5Ј-CTCTGTTGAGACACTTTTGAG-GGTG-3Ј and 5Ј-GCCCAGTGAAGAGCAGGACAGTAGC-3Ј; ␦ subunit, 5Ј-TCCTGCCTGGGATCTTTTCGTTCTGCCCTTGG-3Ј and 5Ј-GGTTT-GTCTTCCCTTCAGCC TGTTGCTGTGGA-3Ј; and ⑀ subunit, 5Ј-TGTG-GTTTCAAGTGTTATTAGAGGCC-3Ј and 5Ј-GAGAAGCAGGGCACCA-AGCAGAGC-3Ј. Primer pairs for subunit coding regions: AChR ␣ subunit, 5Ј-GCACCTGGACCTATGACGGC-3Ј and 5Ј-TAAGACAGAGATG-CTCAGCG-3Ј; AChR ␥ subunit, 5Ј-CAATGTGGACGGTGTCTTCG-3Ј and 5Ј-GTCCAGGAGCATTTTAGCCG-3Ј; AChR ␦ subunit, 5Ј-GTTGT-GTGTGCCCTCCCAGG-3Ј and 5Ј-CAATCTCTGGTAGCCACACC-3Ј; AChR ⑀ subunit, 5Ј-TGATGGGCAGTTTGGAGTGG-3Ј and 5Ј-GAACC-TCCCTCATAGCGGCG-3Ј; ␤-actin, 5Ј-GTTCCGATGCCCTGAGG-3Ј and 5Ј-GAAAGGGTGTAAAACGCAGC-3Ј; and glyceraldehyde-3-phosphate dehydrogenase, 5Ј-TTGAAGGGTGGAGCCAAACG-3Ј and 5Ј-GGGATGACCTTGCCCACAGC-3Ј. All primers were obtained from Life Technologies, Inc..
Cell Culture and Protein Extraction-C2C12, BC3H1, and Sol 8 cells were originally obtained from the American Tissue Culture Collection and maintained in Dulbecco's modified Eagle's medium supplemented with 5% fetal calf serum (Hyclone, Logan, UT) and 15% calf serum, glutamine, and antibiotics (Life Technologies). Mononucleate "earlystage" or "unfused" cells are cells harvested before they reach 70% confluency; these cells are partially differentiated biochemically, because they express myogenin, which is absent from myoblasts (15) . To induce fusion and myotube formation, cells were changed to Dulbecco's modified Eagle's medium and 2% horse serum (Life Technologies) and maintained for 2-4 days, by which time Ͼ90% of cells had fused into myotubes. Nuclear proteins were extracted using the method described by Dignam et al. (24) . Comparable cell samples were used for nuclear protein extraction, chromatin immunoprecipitation, and RNA isolation. and a prestained protein ladder (Life Technologies) were fractionated on a 10% acrylamide gel and subsequently blotted onto polyvinylidene difluoride membranes (Bio-Rad) in a Mini-Trans-Blot apparatus (BioRad). The blots were treated with antibodies to individual MDFs for 2 h at room temperature, followed by mouse anti-rabbit IgG-horseradish peroxidase conjugate (Santa Cruz Biotechnology). Specific bands were detected by chemiluminescence (Chemiluminescence Western blotting kit; Roche Molecular Biochemicals); each experiment was repeated at least three times.
SDS-Polyacrylamide Gel Electrophoresis and Western
Electrophoretic Mobility Shift Assay-PSK-/␣50, the plasmid used for generating the probe, was constructed by cloning 50 base pairs of annealed synthetic oligonucleotides, containing the 36-base pair ␣-subunit enhancer (GGCGGCCCTCAGCTGTCATGCCTGGAACAGGTG-GTG; Ref. 25 ) with its two E boxes (bold) and flanking BamHI linkers, into the SmaI site of Bluescript SKϩ (Stratagene). Labeled probe was generated by excision with BamHI, followed by Klenow fill-in with [␣-32 P]dATP. E R , the sequence surrounding the proximal E box (GCC-
Chromatin Immunoprecipitation (CHIP) Assay-For chromatin immunoprecipitation the protocol of the Farnham (26) and Boss (27) laboratories was adopted. Briefly, formaldehyde was added to cell culture media to a final concentration of 1%; after 10 min the cells were washed with phosphate-buffered saline, collected, and sedimented at 5000 ϫ g for 5 min. The pellet was resuspended in 5 mM 1,4-piperazinediethanesulfonic acid (pH 8.0), 85 mM KCl, 0.5% Nonidet P-40, and a mixture of protease inhibitors (Roche Molecular Biochemicals) at one tablet/10 ml and incubated on ice for 5 min. Nuclei were collected by centrifugation at 5000 ϫ g for 5 min and then resuspended in 50 mM Tris-HCl (pH 8.1), 10 mM EDTA, and 1% SDS and incubated on ice for 10 min. The chromatin was fragmented by sonication to an average size of ϳ600 base pairs. For immunoprecipitation, it was diluted with immunoprecipitation dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, and 167 mM NaCl) and, after addition of 100 g sonicated salmon sperm DNA, 100 g yeast tRNA, and 1 g antibody, rotated end over end at 4°C overnight. Protein A-Sepharose beads were then added to the mixture, and rotation continued for another 2 h. Immune complexes were washed three times for 5 min each with the following buffers: (i) immunoprecipitation dilution buffer; (ii) 2 mM EDTA, 50 mM Tris-HCl (pH 8.1), and 0.2% sarkosyl; (iii) 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.1), and 50 mM NaCl; (iv) 100 mM Tris-HCl (pH 8.1), 500 mM LiCl, 1% Nonidet P-40, and 1% deoxycholic acid; and (v) a final wash with 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA. Immune complexes were disrupted with 50 mM NaHCO 3 and 1% SDS and de-cross-linked by addition of NaCl to a final concentration of 300 mM and heating at 65°C overnight. DNA was ethanol precipitated, treated with proteinase K, extracted with phenolchloroform, and finally ethanol precipitated. The supernatant from the reaction lacking primary antibody was saved as "chromatin input." All experiments were repeated at least twice.
Polymerase Chain Reaction (PCR)-For amplification of E box regions in chromatin samples, 5 l immunoprecipitated DNA (20% of the chromatin preparation) was mixed with 5 l of 10ϫ PCR buffer, 3 l of 25 mM MgCl 2 , 4 l of 2.5 mM dNTP, 5 l each of 5 mM sense and antisense primers, and 1 l Taq polymerase (Promega) in a total volume of 50 l. Amplification was for 35 cycles in a PerkinElmer DNA Thermal Cycler 480; PCR products were separated through a 1% agarose gel, and images were recorded with a digital camera. Each experiment was repeated at least twice. Reverse transcription-PCR was performed to assess AChR subunit gene expression. Total RNA was isolated from C2C12 cells using the RNeasy Mini kit (Qiagen); 1 l of RNA from each sample was incubated (15 min, room temperature) with DNase (RNase-free; Roche Molecular Biochemicals) in 10 l. DNase digestion was stopped by addition of 1 l of 25 mM EDTA, followed by incubation at 65°C for 15 min. Then, 50 pmol (2 l) of random hexamers (Life Technologies) was added to the mixture, and incubation continued at 65°C for 2 min. Treated RNA (6 l) was mixed with 1 unit of Superscript II reverse transcriptase (Life Technologies) in a total volume of 25 l and incubated at 45°C for 1 h to synthesize the first-strand cDNA; 2 l of the cDNA was later used for PCR to check AChR gene expression. The basic PCR procedure was the same as described for CHIP. Each experiment was repeated twice.
RESULTS

Expression of Myogenic Transcription
Factors-To obtain information on which of the myogenic bHLH proteins are present in cultured muscle cells, we performed Westerns blots. C2C12 myotubes contain substantial amounts of all four myogenic factors. BC3H1 cells lack MyoD as expected and display very low levels of herculin; Sol 8 cells express moderate amounts of myogenin and myf-5 and low levels of MyoD and herculin. To determine how the abundance of MDF changes with time, we analyzed C2C12 cells before fusion; such early-stage cells exhibit fair amounts of MyoD and myogenin and a considerable abundance of myf-5, whereas herculin is barely detectable (Fig.  1) . Analysis for myogenin revealed a doublet (Fig. 1) ; the slower-moving band is specifically recognized by anti-phosphoserine antibodies (data not shown) and probably represents a phosphorylated form of myogenin, as previously observed by Zhou and Olson (28) .
In Vitro Binding Analysis-DNA-binding proteins can be identified in cell extracts using appropriate probes and antibodies. We used a section of the chick ␣ subunit promoter for this purpose, because its binding and activation properties are well documented (7, 16, 25, 29) . Two E box-specific band shifts are observed when nuclear proteins extracted from C2C12 cells are electrophoresed with the ␣ subunit enhancer. Both bands, but especially the slower-moving one, are reduced on incubation with anti-MDF antibodies; i.e. the added antibodies do not produce supershifts but instead block complex formation. On the basis of this analysis, MyoD, myogenin, and myf-5 appear mostly as constituents of a slow-moving complex, whereas herculin is present in a higher-mobility band. Not surprisingly, anti-myf-6 has no significant effect in unfused cells, which lack herculin (Fig. 2) .
Detection of Resident Transcription Factors in Vivo Using
Chromatin Immunoprecipitation-To ascertain that myogenic bHLH proteins bind to the enhancer region of AChR genes in vivo, C2C12 cells were treated with formaldehyde and subjected to the CHIP assay protocol. In morphologically differentiated cells all four myogenic factors were found in residence on the ␣, ␦, and ␥ promoters. In unfused cells, MyoD, myogenin, and myf-5 occupied the enhancer regions of the AChR ␣, ␥, and ␦ subunit genes, whereas herculin generated a somewhat weaker signal with ␥ and ␦ and no signal with the ␣ subunit promoter. At AChR ␣, ␥, and ␦ subunit enhancer regions, little change accompanied myotube formation, except that herculin was much more in evidence in myotubes than in unfused C2C12 cells. The ⑀ subunit is unique in that its enhancer appears unoccupied before fusion despite the presence of MDF; however, in myotubes its E box is occupied as indiscriminately as are other subunit E boxes (Fig. 3) . As a control, CHIP was carried out with BC3H1 cells, which are known to lack MyoD; as expected, substantial signals resulted from the use of antibodies to myogenin, myf-5, and herculin, whereas the antiMyoD precipitate harbored no detectable AChR DNA.
Changes in Transcript Levels of AChR Subunit Genes after Fusion-To determine whether AChR promoter occupancy has functional consequences, we assayed for AChR subunit mRNA levels in C2C12 cells. Reverse transcription-PCR measurements revealed the absence of ⑀ subunit expression, low levels of AChR ␣ and ␦ transcripts, and significant amounts of ␥ subunit mRNA in early-stage C2C12 cells; in differentiated myotubes, on the other hand, all subunits were abundantly expressed. No such changes were observed in the expression of housekeeping genes such as ␤-actin and glyceraldehyde-3-phosphate dehydrogenase (Fig. 4) .
DISCUSSION
Much of the research devoted to the expression and activity of the MyoD protein family has suggested considerable functional overlap among family members. To a large extent, arguments concerning the functional distinctness of myogenic factors, i.e. their involvement in the regulation of specific muscle genes, have been based on correlative studies and on results obtained with heterologous expression systems. These observations cannot easily be extrapolated to in vivo events, because muscle cells express several members of this transcription factor family, all of which recognize the same cis element. Our present study demonstrates that all four MDFs bind to the enhancers of AChR subunit genes in vivo and suggests that the functional overlap of these factors arises from actual in vivo competition for the same targets. The up-regulation of a large number of muscle-specific genes during differentiation, including AChR expression, may not require factor specificity.
Rather, it appears that site occupancy is determined by the law of mass action, i.e. by the abundance of individual factors and their affinities for the various CANNTG motifs. In general, every MyoD family protein that is expressed (as quantified by Western blots) is also found to reside at E boxes in the AChR subunit promoters, with the notable exception of the ⑀ promoter in unfused C2C12 cells. Because the ⑀ subunit is not expressed at this stage of muscle development, MDF can be said to be present at the promoters of transcriptionally active receptor genes. This interaction may not be entirely indiscriminate, especially when MDF expression is low, as is the case with herculin in unfused cells. In such early-stage cells herculin binds preferentially to the ␥ subunit promoter, whereas interactions with ␦ and ␣ promoters are less pronounced. Gene activation as a family business is not new; B-cell development, for example, has been shown, albeit less directly, to be dependent not only on an essential function provided by the E2A gene but also on a combined dosage set by E2A, E2-2, and HEB (30) .
Role of Individual MDF-Because MyoD and myf-5 are present in undifferentiated cells that do not express AChR, a reasonable expectation was that another MDF, e.g. myogenin, might be the principal activator of AChR subunit genes. However, within the resolution of the methods used, MyoD, myogenin, and myf-5 behave indistinguishably. The rule that an expressed factor is also a participating factor holds also for the two other cell lines that we investigated. MyoD is absent from BC3H1 cells and consequently is not found at AChR promoters, but the three expressed MDFs are. Myf-5 is strongly up-regulated in BC3H1 cells, as would be expected if the role of MyoD is to suppress the myf-5 gene (1). Strong expression of myf-5 at the mRNA level has been reported for this cell line previously (31) . Sol 8 cells, derived from the slow soleus muscle (32), do not express detectable levels of MyoD. This agrees with earlier observations, which link MyoD to the fast fiber types IIa and IIX in fast muscles (33, 34) .
Expression of Individual Subunits-From a factor occupancy point of view, the AChR genes fall into two groups: (i) genes required for the expression of the embryonic or ␥ type of AChR, namely, ␣, ␥, and ␦; and (ii) ⑀, which is unique to the synaptictype AChR. (Among the former, ␥ is distinct in being occupied by herculin as well as being transcribed before the other subunits. Whether this means that herculin or MRF4 is the factor crucially required for AChR expression in normal cells remains to be seen; at any rate, targeted disruption of the MRF4 gene does not prevent receptor expression (1) .) The ⑀ subunit gene is a special case. Its promoter is not occupied by MDF during early stages of development when factor levels prevail that are adequate for targeting other subunit genes. Once the ⑀ gene is active, however, it binds MDF as indiscriminately as the remaining genes. But even here herculin could be playing a unique role for which earlier heterologous expression studies provide tentative support. Thus, Montarras et al. (35) had noted that the time course of expression of MRF4 correlates with the expression pattern of the ⑀ subunit; in addition, Sunyer and Merlie (36) conducted transactivation experiments with recombinant myoD, myogenin, and MRF4 and showed that MRF4 preferentially transactivates the ⑀-promoter.
Can we be sure that a factor present at a promoter is also functional? A discrepancy between binding and activity could arise if the activity of a transcription factor can be modulated while it resides at the promoter. Myogenin, for example, may be inactivated by a kinase while bound to DNA (28) . It is obviously impossible with the information at hand to ascribe, to each different MDF residing on the enhancer E boxes, a specific functional contribution; at the most we can say that every transcriptionally active AChR subunit gene contains MDF associated with its promoter.
We have used the recently developed CHIP assay to directly establish that MDF interact with E boxes in the promoters of AChR subunit genes in vivo. This method promises to be an excellent tool for the investigation of protein-DNA and possibly also protein-protein interactions at specific promoter sites. It may also provide information on covalent modifications of transcription factors and, with further refinement of the method, may yield insights into regulatory processes in tissues as well as cultured cells. Such experiments are currently under way in the laboratory.
